FDA — authorised 10 November 2010
- Application: BLA022505
- Marketing authorisation holder: THERATECHNOLOGIES
- Local brand name: EGRIFTA
- Indication: POWDER — SUBCUTANEOUS
- Status: approved
🇺🇸 Egrifta in United States
FDA authorised Egrifta on 10 November 2010
Marketing authorisations
FDA
- Status: approved
Egrifta in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Egrifta approved in United States?
Yes. FDA authorised it on 10 November 2010; FDA has authorised it.
Who is the marketing authorisation holder for Egrifta in United States?
THERATECHNOLOGIES holds the US marketing authorisation.